RU2017112748A - Композиции онапристона пролонгированного действия и способы - Google Patents

Композиции онапристона пролонгированного действия и способы Download PDF

Info

Publication number
RU2017112748A
RU2017112748A RU2017112748A RU2017112748A RU2017112748A RU 2017112748 A RU2017112748 A RU 2017112748A RU 2017112748 A RU2017112748 A RU 2017112748A RU 2017112748 A RU2017112748 A RU 2017112748A RU 2017112748 A RU2017112748 A RU 2017112748A
Authority
RU
Russia
Prior art keywords
pharmaceutical composition
onapristone
sustained
release pharmaceutical
day
Prior art date
Application number
RU2017112748A
Other languages
English (en)
Russian (ru)
Other versions
RU2017112748A3 (enExample
Inventor
Александер ЖУКИВСКИ
Стефан ПРОНЮК
Original Assignee
Арно Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Арно Терапьютикс, Инк. filed Critical Арно Терапьютикс, Инк.
Publication of RU2017112748A publication Critical patent/RU2017112748A/ru
Publication of RU2017112748A3 publication Critical patent/RU2017112748A3/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2017112748A 2014-11-17 2015-11-16 Композиции онапристона пролонгированного действия и способы RU2017112748A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462080868P 2014-11-17 2014-11-17
US62/080,868 2014-11-17
PCT/US2015/060940 WO2016081383A1 (en) 2014-11-17 2015-11-16 Onapristone extended-release compositions and methods

Publications (2)

Publication Number Publication Date
RU2017112748A true RU2017112748A (ru) 2018-12-19
RU2017112748A3 RU2017112748A3 (enExample) 2019-06-26

Family

ID=56014429

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017112748A RU2017112748A (ru) 2014-11-17 2015-11-16 Композиции онапристона пролонгированного действия и способы

Country Status (11)

Country Link
US (3) US10786461B2 (enExample)
EP (1) EP3247362A4 (enExample)
JP (1) JP6655075B2 (enExample)
KR (1) KR20170084086A (enExample)
CN (2) CN113559075A (enExample)
AU (2) AU2015350241B2 (enExample)
CA (1) CA2966753A1 (enExample)
HK (1) HK1246653A1 (enExample)
MX (1) MX391191B (enExample)
RU (1) RU2017112748A (enExample)
WO (1) WO2016081383A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113559075A (zh) 2014-11-17 2021-10-29 康泰科思特生物制药公司 奥那司酮延长释放组合物和方法
CA2998924A1 (en) 2015-09-25 2017-03-30 Context Biopharma Inc. Methods of making onapristone intermediates
JP2019503353A (ja) 2015-12-15 2019-02-07 コンテキスト・バイオファーマ・インコーポレイテッド 非晶質オナプリストン組成物およびそれを作製する方法
US20180148471A1 (en) 2016-11-30 2018-05-31 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3321826A1 (de) 1983-06-15 1984-12-20 Schering AG, 1000 Berlin und 4709 Bergkamen 13(alpha)-alkylgonane, deren herstellung und diese enthaltende pharmazeutische praeparate
ES8502612A1 (es) 1983-06-15 1985-02-01 Schering Ag Procedimiento para la preparacion de 13a-alquilgonanos
US4780461A (en) 1983-06-15 1988-10-25 Schering Aktiengesellschaft 13α-alkyl-gonanes, their production, and pharmaceutical preparations containing same
US4742000A (en) 1986-05-02 1988-05-03 University Of Chicago Antibody to human progesterone receptor and diagnostic materials and methods
DE3630030A1 (de) 1986-09-01 1988-03-03 Schering Ag 13(alpha)-alkylgonan-(delta)(pfeil hoch)9(pfeil hoch)(pfeil hoch)((pfeil hoch)(pfeil hoch)1(pfeil hoch)1(pfeil hoch))(pfeil hoch)-5,10-epoxide
US4774236A (en) 1986-09-17 1988-09-27 Research Triangle Institute 17α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and pharmaceutical compositions containing them
IE60780B1 (en) 1987-01-23 1994-08-10 Akzo Nv New 11-aryl steroid derivatives
DE3822770A1 (de) 1988-07-01 1990-01-04 Schering Ag 13-alkyl-11ss-phenylgonane
US5283190A (en) 1989-07-31 1994-02-01 Traish Adbulmaged M Specific monoclonal antibodies against a defined epitope of progesterone receptor and methods for their use
DE4008584A1 (de) 1990-03-15 1991-09-26 Schering Ag Verfahren zur herstellung von zwischenprodukten fuer die antigestagensynthese (onapristonsynthese)
US5141961A (en) 1991-06-27 1992-08-25 Richrdson-Vicks Inc. Process for solubilizing difficulty soluble pharmaceutical actives
MX9301121A (es) 1992-03-02 1993-09-01 Schering Ag Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.
CN1053450C (zh) 1992-11-19 2000-06-14 北京第三制药厂 17位取代11β-取代芳香基-4,9-雌甾二烯类化合物的全合成法
DE4332283A1 (de) 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
EP0787002B1 (de) * 1994-10-24 2006-12-13 Schering Aktiengesellschaft Kompetitive progesteronantagonisten zur bedarfsorientierten weiblichen fertilitätskontrolle
US5759577A (en) 1995-01-17 1998-06-02 American Home Products Corporation Controlled release of steroids from sugar coatings
US6900193B1 (en) 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
IL122740A (en) 1997-01-15 2003-09-17 Akzo Nobel Nv 16-hydroxy-11-(substituted phenyl)-estra-9,4-diene derivatives, their preparation and pharmaceutical compositions containing them
US5962444A (en) 1998-05-29 1999-10-05 Research Triangle Institute 17β-nitro-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US6537584B1 (en) 1999-11-12 2003-03-25 Macromed, Inc. Polymer blends that swell in an acidic environment and deswell in a basic environment
PT1282443E (pt) 2000-05-19 2009-12-04 Genentech Inc Análise de detecção génica para melhorar a probabilidade de uma resposta eficaz a uma terapia do cancro com um antagonista de erbb
US6750015B2 (en) 2000-06-28 2004-06-15 Kathryn B. Horwitz Progesterone receptor-regulated gene expression and methods related thereto
UY26966A1 (es) 2000-10-18 2002-06-20 Schering Ag Uso de antiprogestinas para la inducción de apoptosis en una célula
US7381976B2 (en) 2001-03-13 2008-06-03 Triton Thalassic Technologies, Inc. Monochromatic fluid treatment systems
AUPR546801A0 (en) 2001-06-05 2001-06-28 Commonwealth Scientific And Industrial Research Organisation Recombinant antibodies
US7105642B2 (en) 2001-08-03 2006-09-12 Cell Signalling Technology, Inc. Monoclonal antibodies specific for phosphorylated estrogen receptor alpha (Ser118) and uses thereof
US20040121304A1 (en) 2001-12-21 2004-06-24 Ulrike Fuhrmann Method for screening for progesterone receptor isoform-specific ligands and for tissue-selective progesterone receptor ligands
AU2004217988C1 (en) 2003-02-28 2010-06-03 Southwest Foundation For Biomedical Research Method for preparing 17 alpha-acetoxy-11beta-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, intermediates thereof, and methods for the preparation of such intermediates
US20040265371A1 (en) 2003-06-25 2004-12-30 Looney Dwayne Lee Hemostatic devices and methods of making same
US7247625B2 (en) * 2003-10-09 2007-07-24 Wyeth 6-amino-1,4-dihydro-benzo[d][1,3] oxazin-2-ones and analogs useful as progesterone receptor modulators
DE602005026290D1 (de) 2004-07-09 2011-03-24 Population Council Inc Zusammensetzungen mit verzögerter freisetzung mit progesteron-rezeptormodulatoren
BRPI0515562A (pt) 2004-09-22 2008-07-29 Tripath Imaging Inc métodos e composições para avaliação do prognóstico do cáncer de mama
CA2604218A1 (en) 2005-04-20 2006-10-26 Pfizer Limited Pyrazole derivatives as progesterone receptor antagonists
WO2007078599A2 (en) 2005-12-16 2007-07-12 The Board Of Trustees Of The Leland Stanford Junior University Functional arrays for high throughput characterization of gene expression regulatory elements
US20070167971A1 (en) 2006-01-17 2007-07-19 Raymond Huey Devices and methods for promoting the formation of blood clots in esophageal varices
US20070166372A1 (en) 2006-01-19 2007-07-19 Mai De Ltd. Preparation of solid coprecipitates of amorphous valsartan
AU2007217094A1 (en) 2006-02-17 2007-08-30 Janssen Pharmaceutica N.V. 11-phosphorous steroid derivatives useful as progesterone receptor modulators
DE102006054535A1 (de) 2006-11-15 2008-05-21 Bayer Schering Pharma Aktiengesellschaft Progesteronrezeptorantagonisten
WO2008128783A2 (en) 2007-04-24 2008-10-30 Dsm Ip Assets B.V. Photochemical process for the preparation of a previtamin d
CA2596204C (en) 2007-08-07 2019-02-26 Historx, Inc. Method and system for determining an optimal dilution of a reagent
WO2009025759A1 (en) 2007-08-17 2009-02-26 Progenics Pharmaceuticals (Nevada), Inc. Tight junction proteins associated with infection and entry of hepatitis c virus (hcv), methods and uses thereof
TW200927142A (en) * 2007-10-12 2009-07-01 Novartis Ag Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
EP2075246A1 (en) 2007-12-27 2009-07-01 M. J. Institute of Research A process for preparation of amorphous form of atorvastatin hemi-calcium salt
CN101939009B (zh) 2008-02-05 2013-07-17 哈博生物科学公司 药学固体形式
TW201002736A (en) 2008-04-28 2010-01-16 Repros Therapeutics Inc Compositions and methods for treating progesterone-dependent conditions
TWI539953B (zh) 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
EP2412662A4 (en) 2009-03-27 2017-03-29 Komatsu Ltd. Fuel saving control device for working machine and fuel saving control method for working machine
WO2010126590A1 (en) 2009-04-27 2010-11-04 Cold Spring Harbor Laboratory Ptp1b inhibitors
WO2010141485A1 (en) 2009-06-01 2010-12-09 Samuel Waxman Cancer Research Foundation Compositions and methods to induce differentiation and growth inhibition in breast cancer
MX2012000680A (es) 2009-07-15 2012-02-28 S Bio Pte Ltd Sal de citrato de 9e-15-(2-pirrolidin-1-il-etoxi)-7,12,25-trioxa-1 9,21,24-triaza-tetraciclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2 ,4,9,14,16,18(26),20,22-nonaeno.
US20110293511A1 (en) 2009-09-29 2011-12-01 Terrance Grant Johns Specific binding proteins and uses thereof
US8261855B2 (en) * 2009-11-11 2012-09-11 Flanders Electric, Ltd. Methods and systems for drilling boreholes
WO2011084513A2 (en) 2009-12-15 2011-07-14 Bind Biosciences, Inc. Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
JP5894143B2 (ja) 2010-03-22 2016-03-23 リプロス セラピューティクス インコーポレイテッド 抗黄体ホルモンの無毒送達のための組成物および方法
AU2011325956B2 (en) 2010-11-12 2016-07-14 The General Hospital Corporation Polycomb-associated non-coding RNAs
US20140018404A1 (en) 2010-12-16 2014-01-16 Celgene Corporation Controlled release oral dosage forms of poorly soluble drugs and uses thereof
CA2822462A1 (en) 2010-12-20 2012-06-28 The General Hospital Corporation Polycomb-associated non-coding rnas
WO2012122514A1 (en) 2011-03-09 2012-09-13 Centrose, Llc Extracellular targeted drug conjugates
PT2683384E (pt) * 2011-03-11 2016-03-11 Celgene Corp Métodos de tratamento de cancro utilizando 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidina-2,6-diona
US9618512B2 (en) 2011-04-15 2017-04-11 J-Pharma Co., Ltd. Biomarker for breast cancer
HUE028603T2 (en) 2011-05-13 2016-12-28 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer expressing claudin 6
US20130029953A1 (en) * 2011-07-28 2013-01-31 Klaus Nickisch Progesterone antagonists
WO2013052652A1 (en) 2011-10-04 2013-04-11 Erard Gilles Methods and systems for identifying and treating anti-progestin sensitive tumors
BR112014013709A2 (pt) 2011-12-08 2017-08-22 Fund Sales Métodos, composições farmaceuticas, e kits, para tratar cânceres resitentes às antiprogestinas
US20130338016A1 (en) 2012-04-17 2013-12-19 Vala Sciences, Inc. Method For Integrated Pathology Diagnosis And Digital Biomarker Pattern Analysis
RU2014147625A (ru) 2012-04-27 2016-06-20 Реджентс Оф Зэ Юниверсити Оф Миннесота Прогнозирование рака молочной железы, предсказание подтипа прогестероновых рецепторов и предсказание ответа на лечение антипрогестином на основании генной экспрессии
AU2013295815A1 (en) 2012-07-24 2015-02-05 Cedars-Sinai Medical Center A novel method to detect resistance to chemotherapy in patients with lung cancer
AU2013358968B2 (en) 2012-12-13 2017-12-21 Warsaw Orthopedic, Inc. Compositions and methods comprising polyethylene glycol and magnesium for treatment of neuronal injury
KR20150130359A (ko) 2013-03-12 2015-11-23 아르노 테라퓨틱스 오나프리스톤 다형태 및 사용 방법
US20140363425A1 (en) 2013-03-13 2014-12-11 J. Dinny Graham Systems and methods for identifying cancers having activated progesterone receptors
US9096641B2 (en) 2013-06-05 2015-08-04 Evestra, Inc. Imidazolyl progesterone antagonists
CN103483449A (zh) 2013-08-20 2014-01-01 东北农业大学 两种scFv抗体、其编码基因及其在制备治疗或预防鸡传染性法氏囊病制剂中的应用
CA2939241A1 (en) 2014-04-08 2015-10-15 Arno Therapeutics, Inc. Systems and methods for identifying progesterone receptor subtypes
CN113559075A (zh) 2014-11-17 2021-10-29 康泰科思特生物制药公司 奥那司酮延长释放组合物和方法
EP3273983B1 (en) 2015-03-23 2021-05-05 Evestra, Inc. Novel cytotoxic agents that preferentially target leukemia inhibitory factor (lif) for the treatment of malignancies and as new contraceptive agents
CA2998924A1 (en) 2015-09-25 2017-03-30 Context Biopharma Inc. Methods of making onapristone intermediates
JP2019503353A (ja) 2015-12-15 2019-02-07 コンテキスト・バイオファーマ・インコーポレイテッド 非晶質オナプリストン組成物およびそれを作製する方法
JP2019513706A (ja) 2016-03-21 2019-05-30 コンテキスト・バイオファーマ・インコーポレイテッド オナプリストン代謝物質組成物及び方法
JP7082065B2 (ja) 2016-05-02 2022-06-07 テトラジェネティクス, インコーポレイテッド 抗Kv1.3抗体ならびにその産生方法および使用方法
WO2018067198A1 (en) 2016-10-03 2018-04-12 The Regents Of The University Of California Inhibitory antibodies and methods of use thereof

Also Published As

Publication number Publication date
AU2015350241B2 (en) 2021-05-20
RU2017112748A3 (enExample) 2019-06-26
CN113559075A (zh) 2021-10-29
EP3247362A1 (en) 2017-11-29
KR20170084086A (ko) 2017-07-19
MX2017005163A (es) 2018-01-18
AU2015350241A1 (en) 2017-05-04
WO2016081383A1 (en) 2016-05-26
EP3247362A4 (en) 2018-10-10
US10786461B2 (en) 2020-09-29
JP6655075B2 (ja) 2020-02-26
US20210220279A1 (en) 2021-07-22
JP2017537883A (ja) 2017-12-21
CN106999501B (zh) 2021-08-13
HK1246653A1 (zh) 2018-09-14
US20160166583A1 (en) 2016-06-16
US20230157960A1 (en) 2023-05-25
AU2021218093A1 (en) 2021-09-09
CN106999501A (zh) 2017-08-01
US11672762B2 (en) 2023-06-13
CA2966753A1 (en) 2016-05-26
MX391191B (es) 2025-03-21

Similar Documents

Publication Publication Date Title
NZ777261A (en) Combination of dextromethorphan and bupropion for treating depression
HK1221646A1 (zh) 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
RU2014111069A (ru) Лекарственные формы ингибитора гистондиацетилазы в комбинации с бендамутином и их применение
JP2018507243A5 (enExample)
EA201590166A8 (ru) Комбинированная терапия для лечения рассеянного склероза
RU2017134443A (ru) Способ лечения с применением традипитанта
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
HRP20192189T1 (hr) Doziranja i terapijske primjene l-4-klorokinurenina
RU2014150942A (ru) Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона
PH12018550210A1 (en) Oral dosage form with drug composition, barrier layer and drug layer
WO2014160216A3 (en) Dual targeting anticancer agents
RU2017112748A (ru) Композиции онапристона пролонгированного действия и способы
FI3352735T3 (fi) Pitkitetysti vapauttavia olantsapiiniformulaatioita
JP2016505050A5 (enExample)
RU2018146504A (ru) Лечение внутрипеченочных холестатических заболеваний
MX2013003523A (es) Composicion farmaceutica de dosis baja.
MX391602B (es) Composicion farmaceutica con antagonista del receptor de mineralocorticoides y su uso
RU2018114457A (ru) Лечение syd985 пациентов с t-dm1 рефрактерным раком
RU2020108631A (ru) Новая вспомогательная терапия для применения в способе лечения рака простаты
JP2016514706A5 (enExample)
RU2010154623A (ru) Производные 1-аминоалкилциклогексана для лечения расстройств сна
RU2016145411A (ru) Комбинация брекспипразола и налмефена, и ее применение для лечения синдрома химической зависимости
RU2013148539A (ru) Алиспоривир для лечения инфекции вируса гепатита с
MX340005B (es) Composicion de yodo molecular de uso humano para la prevencion y tratamiento de patologias prostaticas.
RU2015140501A (ru) Фармацевтические композиции на основе донепезила, характеризующиеся специфическим профилем растворимости in vitro или фармакокинетическими параметрами

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20191022